Amgen to buy Celgene's Psoriasis drug for $13.4 billion

Amgen, Celgene, and Bristol-Myers are popping after Amgen announced it will acquire Celgene’s Psoriasis medication Otezla for $13.4 billion in cash. The deal paves the way for Bristol-Myers Squibb to move forward with its merger with Celgene. Yahoo Finance’s Akiko Fujita and Jared Blikre discuss.